Neumora Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Cash & Equivalents	375.25	242.21	409.37
Short-Term Investments	79.94	130.94	0
Cash & Cash Equivalents	455.2	373.15	409.37
Cash Growth	21.99%	-8.85%	-
Other Current Assets	23.08	14.81	6.23
Total Current Assets	478.28	387.96	415.6
Property, Plant & Equipment	6.86	10.64	4.04
Long-Term Investments	9.85	23.51	0
Other Long-Term Assets	1.21	4.13	9.65
Total Long-Term Assets	17.92	38.28	13.69
Total Assets	496.2	426.23	429.3
Accounts Payable	0.34	7.15	1.64
Current Debt	3.38	3.37	1.06
Other Current Liabilities	21.4	13.18	20.58
Total Current Liabilities	25.11	23.7	23.28
Long-Term Debt	1.85	5.07	1
Other Long-Term Liabilities	0.16	0.63	0.39
Total Long-Term Liabilities	2.01	5.7	1.38
Total Liabilities	27.12	29.4	24.66
Total Debt	5.23	8.44	2.05
Debt Growth	-38.04%	311.40%	-
Retained Earnings	-703.43	-467.51	-336.61
Comprehensive Income	-0.08	-0.77	0
Shareholders' Equity	469.08	-446.85	-325.22
Net Cash / Debt	449.96	364.71	407.32
Net Cash / Debt Growth	23.38%	-10.46%	-
Net Cash Per Share	6.92	13.40	2.37
Working Capital	453.17	364.26	392.33
Book Value Per Share	7.21	-16.42	-1.89

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).